News | August 08, 2022
Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The plant is scheduled to come on stream in September 2024
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
